KEYTRUDA (Pembrolizumab)-100mg

KEYTRUDA (Pembrolizumab) is an immunotherapy that works by blocking the PD-1, a protein that prevents T cells from recognizing and attacking inflamed tissues and cancer cells. By blocking PD-1, pembrolizumab increases your immune system’s ability to attack melanoma cells and tumors. The drug works to unleash T cells so that they can invade melanoma anywhere in your body.

Pembrolizumab is a monoclonal antibody, an anti-PD-1 (checkpoint) inhibitor that promotes the tumor-killing effects of T cells (white blood cells that help your body fight disease) and is indicated for:

  • Treatment of recurrent or metastatic cervical cancer
  • Treatment of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
  • As an adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection (melanoma skin cancer)
  • Treatment of patients with metastatic non-small cell lung cancer (NSCLC)
  • Bladder cancer
  • Hodgkin lymphoma
Enquiry Now

Additional information

Trade Name


Generic Name



MSD Pharmaceuticals Pvt Ltd

Drug Type



Lung Cancer

Doasage Form



1 x 100mg/ 4ml